Lilly’s Jaypirca received a label expansion for use as a first-line therapy in chronic lymphocytic leukemia, marking another step for the BTK/CDK pathway strategy in earlier lines of treatment. The update tightens the competitive landscape as oncologists shift toward targeted regimens earlier in disease course.